Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Do institutionals and insiders have more ownership in OVID or CLLS?

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts rate OVID or CLLS?

Ovid Therapeutics currently has a consensus target price of $3.10, suggesting a potential upside of 219.59%. Cellectis has a consensus target price of $4.00, suggesting a potential upside of 40.35%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Cellectis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation and earnings, OVID or CLLS?

Ovid Therapeutics has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$6.65M	10.37	-$26.43M	-$0.53	-1.83
Cellectis	$56.30M	2.81	-$36.76M	-$0.82	-3.48

Is OVID or CLLS more profitable?

Cellectis has a net margin of -100.69% compared to Ovid Therapeutics' net margin of -574.44%. Ovid Therapeutics' return on equity of -58.87% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-574.44%	-58.87%	-43.18%
Cellectis	-100.69%	-68.05%	-21.53%

Which has more volatility and risk, OVID or CLLS?

Ovid Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500.

Does the media prefer OVID or CLLS?

In the previous week, Ovid Therapeutics had 11 more articles in the media than Cellectis. MarketBeat recorded 14 mentions for Ovid Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.24 beat Ovid Therapeutics' score of 0.33 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats Cellectis on 11 of the 17 factors compared between the two stocks.